meeting in Brussels on October 26-27, exactly a year after the Second International Conference on Harmonization in Florida, the ICH Steering Committee has said it will extend its work on harmonization into the field of regulatory communication. The meeting included over 200 experts from the regulatory agencies and industry in the European Union, Japan and the USA to advise the Steering Committee, which also recommended the following harmonized tripartite guidelines as final:
- the extent of population exposure to assess clinical safety: guidance on numbers of subjects and duration required to assess safety through clinical trial programs;
- clinical safety data management - definitions and standards for expedited reporting: harmonization of key elements necessary for international reporting of adverse drug reactions;
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze